Close Menu

UPenn

Nearly 3,500 patients were referred to the Roberts Individualized Medical Genetics Center for exome sequencing or other testing during the clinical program's first four years.

UPenn researchers believe that their lateral flow assay has the potential to be the first point-of-care test that can detect fentanyl and its metabolite, norfentanyl, at clinically relevant cutoffs.

A UPenn research team has developed a proof-of-principle detection platform that uses microbubbles to make target protein molecules visible and detectable.

Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.

A year-long clinical trial at three hospitals found that price transparency alone may not lead to significant changes in a clinician's test requests.  

Research using the T2Plex instrument has detected a new conformation of red blood cells indicating a tight clot, which could be used as a biomarker.

The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.